VRAX
Virax Biolabs Group Limited
NASDAQ · Healthcare · Biotechnology · GB
$2.63
+2.54%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 150.59x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 0.28x
- Price / sales
- 102.74x
- Price / cash flow
- -0.17x
Enterprise value
- Enterprise value
- -$4.3M
- EV / sales
- -208.92x
- EV / EBITDA
- 0.31x
- EV / EBIT
- 0.28x
- Market cap
- $2.1M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Mar 1, 2026